'Sun Pharma Shares' - 118 News Result(s)

  • Sensex Falls 286 Points on Selloff in Metal Shares
    Sensex Falls 286 Points on Selloff in Metal Shares

    UPL, Sun TV Network, MRPL, Jidal Steel, NALCO, Torrent Pharma, JSW Steel and Glenmark were among the losers from the mid-cap space, down 3-4.6 per cent each.

  • TCS, Sun Pharma, 7 Others Lose Rs 78,511 Crore in Market Value
    TCS, Sun Pharma, 7 Others Lose Rs 78,511 Crore in Market Value

    Overall weakness in the equity market dragged down the combined market valuation of nine of the top ten most valued Indian companies by a whopping Rs 78,511.56 crore for the week ended January 8.

  • Sensex Edges Higher in Listless Trading Session
    Sensex Edges Higher in Listless Trading Session

    Some amount of buying was visible in realty, pharma, media and infrastructure shares while mild selling pressure was seen in select metal, IT and banking stocks.

  • Buy Rel Power, Sun TV; Sell Sun Pharma: Sarvendra Srivastava
    Buy Rel Power, Sun TV; Sell Sun Pharma: Sarvendra Srivastava

    Sarvendra Srivastava, CMT-head technical research at Phisense.com, says the Nifty has managed to close above the important 7,850 levels in the holiday-shortened week (December 21-24) despite weak volumes.

  • Sun Pharma Shares Rebound on Value-Buying
    Sun Pharma Shares Rebound on Value-Buying

    Shares of Sun Pharma rebounded on Tuesday after slumping 4.5 per cent on Monday. Shares of India's biggest pharma company gained as much as 2 per cent today on value-buying at lower levels.

  • Sun Pharma Slumps After US Issues New Reprimand to India Drug Industry
    Sun Pharma Slumps After US Issues New Reprimand to India Drug Industry

    Shares in India's largest drugmaker, Sun Pharmaceutical Industries Ltd, skidded more than 7 percent on Monday after U.S. regulators warned of standards violations at a key plant in the latest blow to India's generic drug industry.

  • Sensex Ends 217 Points Higher, Led by Gains in Banking Shares
    Sensex Ends 217 Points Higher, Led by Gains in Banking Shares

    The Sensex rose 217 points to close at 25,736 and the 50-share Nifty advanced 72 points to settle at 7,834 on the back of gains in banking, metal and IT shares.

  • Sun Pharmaceutical Industries Shares Sink on FDA Warning Letter
    Sun Pharmaceutical Industries Shares Sink on FDA Warning Letter

    The US Food and Drug Administration's (US FDA) warning letter to Sun Pharma indicates the agency is dissatisfied with the remedial measures the company has implemented since last September, when the FDA first notified the company of its concerns after an inspection.

  • Sun Pharma Gains on Sale of US Manufacturing Unit
    Sun Pharma Gains on Sale of US Manufacturing Unit

    However, the company did not disclose the financial details of the transaction. Sun Pharma said impact of this development on its financials will be negligible.

  • Sun Pharma Inks Pact to Develop Nervous System Drugs
    Sun Pharma Inks Pact to Develop Nervous System Drugs

    Scientists at Weizmann Institute have developed a recombinant enzyme currently undergoing animal studies for indications of brain stroke and glioblastoma.

  • Sun Pharma Extends Rally on Anti-Cancer Drug Approval
    Sun Pharma Extends Rally on Anti-Cancer Drug Approval

    Sun Pharma shares have underperformed the broader Nifty in the last three months as the company is struggling with issues at its Halol manufacturing facility, Ranbaxy integration as well as pricing pressure in the United States, the company's largest market.

  • Sun Pharma Gets US Regulator's Nod for Cancer Treatment Drug
    Sun Pharma Gets US Regulator's Nod for Cancer Treatment Drug

    Drug major Sun Pharmaceutical Industries on Friday said one of its subsidiaries has received approval of the US Food and Drug Administration (FDA) to manufacture and market generic version of Novartis' Gleevec, used in treatment of cancer, in America.

  • Sun Pharma Surges Over 6% on New Drug Approval
    Sun Pharma Surges Over 6% on New Drug Approval

    Sun Pharma is expected to commercially launch the product on February 1, 2016. "Under the terms of a settlement agreement with Novartis, the Sun Pharma subsidiary is permitted to launch its version of generic Gleevec in the United States on February 1, 2016," the company said.

  • Sun Pharma Surges After Taro Drops Wind Energy Plans
    Sun Pharma Surges After Taro Drops Wind Energy Plans

    Shares of Sun Pharma surged as much as 4.5 per cent to Rs 739 after its US-listed subsidiary Taro decided not to proceed with investment in wind energy projects.

  • Sun Pharma, Dr. Reddy's Lab Shares Slump on Compliance Worries
    Sun Pharma, Dr. Reddy's Lab Shares Slump on Compliance Worries

    The two drugmakers did not give any deadline for the issues to be resolved. Kotak analysts, however, estimate Sun Pharma's Halol site - a site it had owned before the Ranbaxy deal - could be cleared by the second half of 2016.

  • Sun Pharma Skids Over 7% as Q2 Net Dips
    Sun Pharma Skids Over 7% as Q2 Net Dips

    Consolidated net sales of the company declined to Rs 6,803.31 crore for the quarter under consideration as against Rs 7,979.31 crore for the same period a year ago.

  • Sun Pharma Completes Acquisition of InSite Vision
    Sun Pharma Completes Acquisition of InSite Vision

    Drug major Sun Pharmaceutical Industries on Tuesday said it has completed acquisition of US-based eye care firm InSite Vision.

  • Sun Pharma Falls 3% on Cautious FY16 Outlook
    Sun Pharma Falls 3% on Cautious FY16 Outlook

    Sun Pharma shares fell over 3 per cent on Monday after India's biggest pharma company said it expects revenues and net profit to be adversely hit in the short term due to supply constraints at its Halol facility in Gujarat and high expenses arising out of Ranbaxy integration as well as remedial actions.

  • Sun Pharma's Tender Offer for InSite Ends, to Directly Acquire Shares
    Sun Pharma's Tender Offer for InSite Ends, to Directly Acquire Shares

    Sun Pharmaceutical Industries on Wednesday said its arm Thea Acquisition Corp plans to exercise a 'top-up' option to purchase shares directly from eyecare firm InSite Vision to hold a 90 per cent stake in the US-based company to complete a merger, after failing to get the required number of shares through a tender offer.

  • Sun Pharma Rises After Settling Patent Litigation With Actavis
    Sun Pharma Rises After Settling Patent Litigation With Actavis

    Shares of Sun Pharma gained as much as 2 per cent on Tuesday after Ranbaxy Pharmaceuticals, a unit of India's biggest pharma company, settled a patent litigation with Actavis over the generic version of Absorica, which is used to treat acne.

Advertisement

Advertisement

Market Data provided by © Accord Fintech.
© Copyright NDTV Convergence Limited 2016. All rights reserved.